Phase 2 · Retatrutide

NCT05936151 trial results

Last updated

A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24 (mL/min/1.73 m²), Baseline, Week 24. Placebo: -0.19; Retatrutide: -1.62.

Participants
146
Status
completed
Completed
2025-10-21
Sponsor
Eli Lilly and Company

As posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Primary outcome

What NCT05936151 measured first

Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24mL/min/1.73 m² · Baseline, Week 24 · least squares mean
Placebon=58Retatrutiden=55
-0.19(2.690)-1.62(2.820)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Side effects by arm

Side effects in NCT05936151

Percent of participants affected, Baseline up to end of follow-up (up to 28 weeks). The most common events the registry lists.

EventPlaceboRetatrutide
Any serious event8.7%12.3%
Diarrhoea5.8%13.7%
Nausea5.8%9.6%
Decreased appetite0%8.2%
Gastrooesophageal reflux disease0%5.5%
Hypotension4.3%5.5%

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Secondary outcomes

What else it measured

Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 16mL/min/1.73 m² · Baseline, Week 16 · least squares mean
Placebon=58Retatrutiden=55
-4.08(1.923)-4.34(1.993)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24Percent change · Baseline, Week 24 · geometric least squares mean
Placebon=19Retatrutiden=23
-8.75(17.575)-53.65(8.267)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Change From Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa) at Week 24Percentage of FENa · Baseline, Week 24 · least squares mean
Placebon=61Retatrutiden=55
0.06(0.075)-0.23(0.082)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Change From Baseline in Filtration Fraction Estimated From Measured Glomerular Filtration Rate (mGFR) and MRI-Assessed Renal Mean Arterial Flow, Corrected by Hematocrit at Week 24Unitless · Baseline, Week 24 · least squares mean
Placebon=55Retatrutiden=53
-0.01(0.008)-0.02(0.008)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Change From Baseline in Mean Arterial Flow (MAF) at Week 24Milliliter/Minute (mL/min) · Baseline, Week 24 · least squares mean
Placebon=60Retatrutiden=62
0.6(22.37)-6.9(22.25)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Change From Baseline in Renal Artery Resistive Index (RARI) at Week 24Unitless · Baseline, Week 24 · least squares mean
Placebon=59Retatrutiden=62
0.02(0.008)-0.02(0.008)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Change From Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) at Week 24centimeters per second (cm/s) · Baseline, Week 24 · least squares mean
Placebon=59Retatrutiden=62
1.12(1.790)-2.12(1.762)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Change From Baseline in Renal Blood Flow Velocity End-Diastolic Velocity (EDV) at Week 24cm/s · Baseline, Week 24 · least squares mean
Placebon=59Retatrutiden=62
-0.58(0.442)0.33(0.436)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Percent Change From Baseline in Total Renal Parenchyma Volume (MRI) at Week 24Percent change · Baseline, Week 24 · least squares mean
Placebon=62Retatrutiden=59
0.19(1.016)-5.95(1.053)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Percent Change From Baseline in Renal Cortex Volume (MRI) at Week 24Percent change · Baseline, Week 24 · least squares mean
Placebon=61Retatrutiden=58
0.40(1.162)-8.38(1.206)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Percent Change From Baseline in Kidney Parenchyma Global Perfusion (MRI) at Week 24Percent change · Baseline, Week 24 · least squares mean
Placebon=59Retatrutiden=58
2.58(2.971)8.09(3.033)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Percent Change From Baseline in Renal Cortex T1 (MRI) at Week 24Percent change · Baseline, Week 24 · least squares mean
Placebon=59Retatrutiden=58
0.56(0.481)2.82(0.494)

From the results posted on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

The trial

How NCT05936151 was run

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.

  • Retatrutide: Participants received retatrutide administered subcutaneously once weekly for approximately 24 weeks. Treatment was initiated at 2 milligrams (mg) once weekly and escalated every 4 weeks to 4 mg, 6 mg, 9 mg, and 12 mg. The target maintenance dose was 12 mg once weekly. Participants who did not tolerate the 12 mg dose could remain on a maintenance dose of 4 mg, 6 mg, or 9 mg.
  • Placebo: Participants received placebo matched retatrutide administered subcutaneously once weekly for approximately 24 weeks. To maintain blinding, participants followed a sham dose-escalation schedule with changes in administered volume every 4 weeks to match the retatrutide dose-escalation schedule.
Who could join the trial

Inclusion Criteria: * Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²) * Have either * no T2D with an HbA1c \< 6.5% or * have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening. * Have been diagnosed with chronic kidney disease (CKD). Exclusion Criteria: * Have a self-reported change in body weight \>5 kilogram (kg) (11 pounds) within 90 days before screening. * Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin * Have a prior or planned surgical treatment for obesity * Have Type 1 Diabetes (T1D) * Have acute or chronic hepatitis * Have a history of malignant disease within 5 years before screening.

In the trial's own words, from its record on ClinicalTrials.gov (NCT05936151) (clinicaltrials.gov/study/NCT05936151), updated at source Nov 9, 2026.

Published papers

Papers from NCT05936151

  • Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026 May 29;41(6):1058-1068. doi: 10.1093/ndt/gfaf230. (pubmed.ncbi.nlm.nih.gov/41160422)

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.